Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00297804

A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions (TAXUS VI)

TAXUS VI - A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions

Sponsor: Boston Scientific Corporation

Interventions Control stent TAXUS Express Paclitaxel-Eluting Coronary Stent System

Updated 7 times since 2017 Last updated: Apr 20, 2017 Started: May 31, 2002 Primary completion: Oct 31, 2003 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Coronary Artery Disease and is currently completed. Boston Scientific Corporation leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
May 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Mar 2017 — May 2017 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Mar 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boston Scientific Corporation

Data source: Boston Scientific Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Siegburg, Germany